The high incidence of vascular complications in patients with diabetes mellitus remains incompletely understood. Several metabolic or endocrine abnormalities have been postulated as possible triggers for micro and macroangiopathies. This review article focuses on the consequences of hyperglycemia, leading to the formation of advanced glycation endproducts (AGE), on vascular function. Advanced glycation endproducts are the product of the binding of aldoses onto free amino groups of proteins or lipoproteins, which, after molecular rearrangement, result in a class of molecules of a brown color and specific fluorescence. Different cell membrane proteins have been shown to bind AGE and the best characterized receptor for AGE has been named RAGE. The AGE receptor is present on different cell types including endothelial cells, smooth muscle cells, lymphocytes and monocytes.
Introduction
The high incidence of vascular complications in patients with diabetes mellitus has prompted researchers to look for a relationship between vascular dysfunction and diabetes mellitus. Several hypotheses relating to hyperglycemia have been proposed: the sorbitol hypothesis, the diacyl glycerol pathway, the non-enzymatic glycation of proteins and an alteration of the redox potential. Other mechanisms have also been postulated. Insulin-like growth factor, produced in excess, can participate in the genesis of the retinopathy observed in diabetic patients. Excess of insulin secondary to insulin treatment in type 1 diabetes or inappropriate secretion in type 2 has been postulated as one of the factors which may be involved in smooth muscle cell proliferation. Abnormalities of the lipid profile that is frequently found in patients with diabetes mellitus are considered to be one of the major contributing factors in atherosclerosis. 1 Lipoprotein oxidation may occur secondary to the excessive production of reactive oxygen intermediates. These oxidation products can alter endothelial cell functions and are a Biologie Vasculaire et Cellulaire, UFR -Lariboisière -Saint Louis et INTS, Paris, France and b Service de Médecine Interne 2, Hôpital Lariboisière et Faculté de Médecine Lariboisière -Saint Louis, Université Paris VII, France chemotactic for monocytes/macrophages. 2 Despite these possibilities, compelling evidence places hyperglycemia at the origin of several different vascular dysfunctions that are observed in diabetic patients. Observations made in familial galactosemia underline the potentially damaging effects of excess sugar at tissue level. Aldoses and, in particular, glucose, react with the amino groups of molecules to produce a heterogeneous group of molecules named advanced glycation endproducts AGE); this review concentrates on the role of this process on certain aspects of vascular function in diabetes.
Non-enzymatic glycosylation
In 1912, Louis Camille Maillard described, for the first time, a reaction between glucose and amino acids which led to the binding of sugar to the amino group of the protein. Since this first description, the reaction of Maillard was found to be essential for the formation of AGE. A long exposure to hyperglycemia leads to the glycosylation of proteins and lipoproteins by a non-enzymatic pathway. The non-enzymatic glycosylation, or glycation, results in the formation of different classes of heterogeneous sugaramino acids, adducts collectively called AGE.
or Schiff base. The amino groups are located on N-terminal amino acid residues and/or on ⑀ amino groups of the lysine of proteins. The Schiff base may arrange to form more stable products called Amadori products. AGE formation from Amadori products requires the presence of molecular oxygen and therefore does not proceed under anaerobic conditions. The reaction is catalyzed by transition metals, and is inhibited by reducing compounds. Amadori products lead, after intra and intermolecular rearrangements, to a new class of molecules called Maillard products or AGE. The cross-linking of the proteins results in a yellow-brown pigmentation with a characteristic fluorescence spectrum. 3 Advanced glycation endproducts per se generate reactive oxygen intermediates by autoxidation. 4 The chemical structures of the different AGE molecules have not yet been completely defined. Some of those that have been produced in vitro have been fully characterized and can be detected in vivo. 2-(2-fuoryl)-4(5)-(2-furanyl)-1H-imidazole (FFI) is detectable on human globin, albumin and in atherosclerotic lesions. Pentosidine is formed by the cross-linking between l-lysyl and l-arginyl residues and a five-sugar backbone. FFI, pyrrole derivatives and pentosidine can be detected in animal and human tissues by their fluorescent properties.
N-Carboxymethyllysine (CML), FFI and pyrrole derivatives can be immunologically identified. These different post-transcriptional forms co-exist on different carrier proteins such as hemoglobin, albumin and low density lipoproteins. 4
Glycation of proteins
Immunoglobins are glycated differently according to their class. The glycation of immunoglobulin M is twofold greater than that of immunoglobulin G, and could be related to the difference in amino acid composition. Albumin can be glycated at multiple sites. In diabetic patients, excessive glycation of fibrinogen and fibrin has been reported. 4 Quantitative or qualitative abnormalities of lipoproteins have been claimed to have a major role in the development of atherosclerotic lesions. Glycation of apolipoprotein B (Apo B) on the lysine residues within the specific receptor recognition domain or the contiguous amino acid region may alter its metabolism. 5 In patients with diabetes mellitus, AGE-Apo B levels are twofold higher and extremely elevated (24-fold higher) in patients with end-stage renal disease. Diabetes is associated also with lipid oxidation but the causative role of the oxidant radicals is unclear.
The hypothesis that non-enzymatic glycation contributes to lipid peroxidation is supported by the fact that fatty acidderived aldehydes are detected in diabetic patients. 6 Low density lipoproteins oxidation results in a higher clearance by macrophage scavenger receptors and may contribute to the formation of foam cells. 7, 8 When glycated Apo C exhibits an abnormal binding to the B/E receptor. Glycation may have an inhibiting effect on the uptake of triglycerides particles. 9
Cellular receptors for AGE
Using radiolabeled AGE proteins it has been shown that several cells, such as human and mouse monocyte, macro-Vascular Medicine 1998; 3: 131-137 phage and lymphocyte, bind these types of glycated compounds in a relatively selective way. [10] [11] [12] Advanced glycation endproduct proteins bind to these cells in a saturable manner with a dissociation constant in the range of 50-200 mmol/l −1 . The putative receptors for AGE have been isolated from cell membranes and purified, and were reported to have different molecular weights: 30-50 KD for renal tissue, 36-83 KD for a macrophage cell line, 60-90 KD for liver cells. 13, 14 Binding proteins for AGE have been characterized on endothelial cells. At the first attempt, two polypeptides were isolated from bovine lung tissue, one was the receptor for AGE (RAGE) and the other lactoferrin-like peptide. 15, 16 The receptor for AGE, in its truncated soluble form, is a 35-KD-protein which belongs to the immunoglobulin superfamily of cell-surface molecules. The protein consists of one extracellular region with one V-type domain and two C-type domains, a single transmembrane domain and a short, highly charged intracellular region. 17 Chromosomal DNA has been cloned, and recombinant proteins produced in insect cells. Recombinant RAGE molecular weight, as deduced from the DNA sequence, is around 50 KD. 18 The gene for RAGE is localized on chromosome 6 p 21-3 in the human major histocompatibility complex class III region. 19 Human, murine, bovine RAGE have a high homology. 20 The AGE receptor shares significant homology with MUC (Ig-like superfamily member) (immunoglobulin-like superfamily member), the neural adhesion molecule and the CD20 B lymphocyte activation member. 21 The AGE receptor is expressed on different cell types, including monocytes/macrophages, T lymphocytes, endothelial cells, smooth muscle cells, fibroblasts, mesangial cells and neurons. 20 Hyperglycemia, and tumor necrosis factor ␣ stimulate the expression of RAGE. The AGE receptor ligands are not restricted to AGE, amphoterin and substance ␤-amyloid also bind to the receptor. The lactoferrin-like molecule (LFL) is similar to milk-derived lactoferrin and it binds non-covalently, and with higher affinity, to the extracellular domain of RAGE. The complex RAGE-LFL at the endothelial cell surface can mediate the penetration of albumin-AGE in the cell and in the extravascular compartment. 21 A carbohydrate-binding protein of 35 KD named Galectin 3 is present on lymphocytes, macrophages, endothelial, mesangial, smooth muscle cells, and fibroblasts, and binds AGE with a higher affinity than other carbohydrates. 22 
AGE, blood cells and the vessel wall
Red blood cells Glycated hemoglobin (HbA 1 ) has been used for years for monitoring diabetic treatment. Hemoglobin is glycated at two sites: on the valine residue of the N Terminal ␤ chains at the ⑀ amino group of the ␣ and ␤ chains, and at the N termini of the ␣ chains. 23 Other intracellular and membrane proteins of red blood cells (RBC) are also glycated, for example Spectrin, a major RBC membrane protein, band 3 transmembrane protein, and band 4-1. [24] [25] [26] [27] The glycation results in reduced RBC deformability and an increased adherence to endothelium. [28] [29] [30] [31] Anti-AGE antibodies or soluble RAGE inhibit the enhanced adhesion to endothelium when incubated with RBC from diabetic patients. 32 The accelerated clearance of diabetic rat RBC when infused in normal rats is prevented by the infusion of anti-RAGE antibody in the animal. These results support the concept that the abnormal adhesion of RBC taken from diabetics is mediated by AGE present on RBC and RAGE expressed at the endothelial cell surface. 32
Platelets
Platelet membrane proteins can be glycated. The increased binding of fibrinogen and the increased platelet aggregation observed in diabetic patients can be related to the glycation of the adenosine diphosfate receptors, and lipids can also contribute to the modifications of platelet functions in diabetes. 4
AGE in the extracellular matrix and the vessel wall components
Vascular cell function alteration and thickening of the basement membrane is a common feature of the diabetic vasculopathy. Proteins with a low turnover are excellent candidates for glycation. Collagen and elastin both accumulate AGE.
Diabetic microangiopathy
The development of techniques for measuring the flow and permeability of microvessels in man has permitted the study of capillary pressure and microvascular hemodynamics. In insulin-dependent diabetes, increased capillary pressure may result in microvascular sclerosis and could also play an important role in nephropathy. 33, 34 The increase in permeability found in several organs has been shown to be secondary to the AGE-RAGE interaction and to the Reactive oxygen intermediates production (ROI), 34 but it is also known that ketone bodies may alter intestinal vascular permeability.
Diabetic retinopathy
Diabetic retinopathy involves both morphological and functional changes in the retinal capillaries, including basement membrane thickening, loss of pericytes, increased permeability and vascular dysfunction. These alterations result in two components: macular edema due to the leakage of macromolecules such as lipoproteins into the retinal layers, and progressive capillary closure related to microthrombosis ( Figure 1 ). Capillary closure leads to non-perfused hypoxemic retinal areas (ischemic retinopathy) ( Figure 2) , which, in turn, induces the secretion of vascular endothelial growth factor (VEGF) and the development of new vessels (proliferative retinopathy).
The role of chronic hyperglycemia, that is, long-term exposure to high glucose levels in the development of diabetic retinopathy, has been established both in type 1 diabetes mellitus by the Diabetes Control and Complications Trial, 35 and in type 2 diabetes mellitus. 36, 37 Moreover, a positive correlation has been established between the level of hyperglycemia, as assessed by HbA 1 or HbA 1c assay, and the prevalence and the severity of retinal lesions. 38 The role of AGE in the development of retinopathy has been Vascular Medicine 1998; 3: 131-137 suspected for years. In diabetic patients, an increase in skin concentration of pentosidine is associated with the development of proliferative retinopathy. 39 The same holds true for FFI, CML and total fluorescence, which increase in parallel with the increasing severity of retinopathy. 40 The role of AGE in the development of diabetic retinopathy and the effect of the AGE-formation inhibitor, aminoguanidine, have been examined in animal models by Hammes et al. 41, 43 Rats with streptozotocin-induced diabetes develop a characteristic diabetic retinopathy with endothelial cell proliferation, pericyte loss, microaneurysms and capillary closure. Treatment with aminoguanidine started 2 weeks after dia-betes induction results in a dramatic reduction in the development of retinal lesions, with a 80% reduction in pericyte loss, an absence of microaneurysms and endothelial cell proliferation. The accumulation of AGE at the branching sites of precapillary arterioles is also prevented. 41 Also, aminoguinidine has been shown to prevent, in part, the development of retinopathy in another animal model, the diabetic spontaneously hypertensive rat. 42 In this model, the AGE-formation inhibitor completely prevents the deposition of periodic acid Schiff-positive material in arterioles and also prevents the formation of microthrombi. Finally, aminoguanidine is also effective in the secondary prevention of diabetic retinopathy in rats, with treatment starting 6 months after diabetes induction by streptozotocin. 44 The effect is the same as islet transplantation. These results are in close agreement with those of the Diabetic Control and Complications Trial (DCCT), which indicate the efficacy of controlling blood glucose levels in primary as well as in secondary prevention. 36 Other studies have addressed the specific putative mechanisms of AGE toxicity. In vitro, the toxic effects of high glucose concentrations on capillary pericytes have been shown to be inhibited by aminoguanidine, suggesting a role for AGE. 45 Further insight as to the mechanisms involved has come from recent studies which indicate that the toxic effects of AGE on retinal capillary pericytes and endothelial cells in culture can be blocked by RAGE antibodies. 45 A role for VEGF in vascular dysfunction (increased blood flow and vascular permeability) related to pseudo-hypoxemic changes has been suggested by recent experiments. 46 These effects were prevented by neutralizing VEGF antibodies, and markedly reduced by aminoguanidine. Murata et al 47 have observed an association between the accumulation of CML in the human diabetic retina with proliferative and non-proliferative changes and the expression of VEGF, which was assessed by immunochemistry.
The role of AGE in relation to other aspects of functional and morphologic alterations characteristic of diabetic retinopathy has also been investigated. In diabetic rats, Hammes et al 43 have observed a 75% decrease in basement membrane thickening in the retina of animals treated with aminoguanidine compared to non-treated animals, suggesting a role for AGE accumulation. In vitro, an increased vascular permeability is associated with endothelial endocytosis. An increased endocytosis in retinal vascular endothelial cells is observed in a high glucose medium. 48 This increase is markedly reduced by aminoguanidine, suggesting a further role for AGE. In rats with streptozotocininduced diabetes, Cho et al have observed a preventive effect of aminoguanidine on alterations in the blood-retinal barrier when assessed by vitreous fluorophotometry.
Diabetic nephropathy
Diabetic nephropathy is characterized by an abnormal deposit of matrix in the glomerular mesangium, leading to glomerulosclerosis (Figure 3 ). Accumulation of collagenrelated proteins in the glomerular extravascular matrix causes progressive capillary occlusion. The pivotal role of chronic hyperglycemia in the development and progression of nephropathy has been clearly established in type 1 diabetes mellitus by the DCCT. 50 Numerous studies, in both human and experimental diabetes, have investigated the Vascular Medicine 1998; 3: 131-137 putative role of AGE in the development of nephropathy. An increase in serum and tissue AGE levels in parallel with the severity of renal function impairment has been observed by Makita et al. 51 The occurrence of incipient nephropathy has also been shown to be associated with the levels of FFI, CML, pentosidine and with total fluorescence in the skin. 51 Skin AGE levels detected by immunochemistry correlate with the severity of nephropathy and increase in the early stages of the condition. 52 In type 1 diabetes mellitus, a longitudinal study of 2.5 years duration has demonstrated the predictive value of AGE serum levels for the development of the early morphologic changes in the kidney. 53 A direct inhibitory effect of glycated albumin has been observed on mesangial cell proliferation. 54 Prolonged (5 months) AGE infusion in normal rats results in an increase in AGE renal tissue content, in glomerular volume, in basement membrane thickness and in the mesangial extracellular matrix. 55 These changes run parallel with an increase in urinary excretion of albumin and protein. Cotreatment with the AGE-formation inhibitor, aminoguanidine, markedly limits structural and functional alterations. The in vitro data suggest that AGE alter glomerular structure and function, leading to diabetic glomerulosclerosis. The key role for the kidney in AGE metabolism has been documented. 56 An effect of AGE on renal gene expression has also been described. 57 Administration of AGE-modified albumin to normal mice for 4 weeks induces glomerular hypertrophy as well as an increase in glomerular extracellular matrix, ␣ 1 (IV) collagen, laminin B 1 and transforming growth factor ␤ 1 (TGF-␤ 1 ) messenger RNA levels. This response seems to be specific to AGE because all these changes can be prevented by aminoguanidine co-administration. Human mesangial cells express a receptor for AGE. The exposure of normal mouse mesangial cells to AGE albumin induces an increase in collagen IV messenger RNA expression and secretion. This increase in collagen IV production could be mediated, at least in part, by platelet-derived growth factor. 58 The role of AGE in diabetic nephropathy development has been investigated in streptozotocin-induced diabetic rats compared to non-diabetic control rats and to diabetic rats cotreated with aminoguanidine. 59 At 32 weeks, the diabetic rats exhibited increased fluorescence in their glomeruli and renal tubes, which was prevented by aminoguanidine. The diabetic rats developed albuminuria over the 32-week period. This increase was attenuated by aminoguanidine, but not by an antioxidant or by an aldose reductase inhibitor. All these data emphasize the role of AGE and the interaction of AGE-modified proteins with diabetic mesangial cells in the development of glomerulosclerosis.
Multicenter studies evaluating the efficacy of aminoguanidine in diabetic patients with nephropathy are now in progress in Europe and North America, although the inhibitory effects of aminoguanidine on nitric oxide synthase may limit its therapeutic use.
Macroangiopathy
Macrovascular disease, and particularly coronary heart disease, are the main causes of premature death in diabetic patients. A relative risk of 2 to 3 for chronic heart disease and peripheral and cerebrovascular disease has been dem- onstrated in diabetic patients when compared to the general population. 60 The deleterious and specific role of chronic exposure to high glucose levels has been supported by longitudinal studies. [61] [62] [63] [64] Some studies indicate the role of AGE in the development of diabetic cardiovascular and cardiac disease. Advanced glycation endproducts have been identified in the coronary arteries of diabetic patients, particularly in atheromatous lesions, which suggests a role for AGE in the accelerated development of arterial disease in diabetes. 65 An association between increased skin collagen fluorescence and arterial stiffness as well as an increase in systolic and diastolic blood pressure have been reported. 66 These biomechanic alterations are associated with an increase in glycation cross-links. 67 In experimental diabetes, aminoguanidine has been shown to inhibit the formation of the cross-links of collagen in the arterial wall. 68 Decreased arterial and arteriolar elasticity and compliance in diabetes may contribute to the development of hypertension which, together with arterial stiffness, may result in abnormal shear stress predisposing to endothelial injury and early atherogenesis. Furthermore, collagen glycoxidation products appear to quench nitric oxide activity, 69 resulting in impaired endothelium-derived vasodilation and abnormalities in blood flow regulation. Other effects have been studied in animal models. Vascular hypertrophy was observed in streptozotocin-induced diabetic rats, together with an increase in TGF-␤ 1 and ␣ 1 (IV) collagen gene expression. 70 Treatment of diabetic rats with aminoguanidine results in a significant reduction in pathologic changes and in the overexpression of TGF-␤ 1 and ␣ 1 collagen genes.
Conclusion
Advanced glycation endproducts appear to play a critical, if not unique, role in the genesis and/or development of vascular complications in diabetic patients. The binding of AGE to RAGE may alter vessel function in several ways: by facilitating extravasation of AGE proteins or lipoproteins; by increasing vascular permeability; and by inducing leukocyte emigration and macrophage stimulation. The consequences for the micro and macrocirculation are difficult to delineate. The differences in the size of the vessel are not the only variations, and the response of the endothelial cells and the smooth muscle cells may be different according to their location. Using immunologic techniques colocalisation of AGE and RAGE has been demonstrated in the inner plexiform layer and in the inner limiting membrane of the retina, in the media and adventita of the aorta and in the renal glomerulus of diabetic animals. 71 The presence of AGE at sites of diabetic microvascular injury strongly suggests that this interaction may participate in the genesis of vascular complication.
Preventing AGE formation or the consequence of AGEreceptor interaction may be a target for limiting the progression of vascular lesions in patients with diabetes mellitus.
